Display omitted
•~6 nm β-cyclodextrin-conjugated dextran-coated magnetic Ni1.04Fe1.96O4 NPs are prepared.•Enhanced camptothecin loading and sustained release are observed.•Stimuli-responsive ...(pH-dependent) release of the drug from the nanocarrier occurs.•The efficacy of the drug-loaded nanocarrier is intense on cervical, breast, and lung cancer cells.•The material works as a pH-responsive and host: guest complexation-based drug vehicle.
This paper fortifies the idea of smart drug vehicles, by exploring nickel ferrite nanoparticles. The material is made smart by covering with a novel biocompatible dextran fastened with a hydrophobic cavity containing molecule, β-cyclodextrin (β-CD). The approximately 6 nm MNPs, embodied with the β-CD-dextran conjugate, permit a sustained in vitro release of camptothecin. Cytotoxicity studies are done on HaCaT, 3T3, HeLa, MDA-MB-231, and A549 cell lines. It is fascinating the stacked camptothecin indicates upgraded viability against cancer cells, rendering the nanocarrier viable for transporting the anticancer drug.
New cyclometallated ruthenium(ii) complexes of 3-acetyl-7-methoxycoumarin-4
-substituted thiosemicarbazones were synthesized and characterized by analytical and spectral techniques. The crystal ...structures of the ligands H
L
and complexes (1, 2 and 4) were confirmed by X-ray crystallography. The analysis showed that the ligands have undergone C-H activation at the C(4) carbon of the pyrone ring and acted in a tridentate fashion by binding through C, N and S atoms. CT-DNA and protein (BSA/HSA) binding studies were carried out to analyze their interaction with biomolecules. Good binding affinity with DNA was observed with intercalative binding mode, which was further confirmed by EB displacement and viscosity measurement studies. The quenching mechanism with BSA/HSA was found to be static. Three dimensional (3D) fluorescence measurements were carried out to validate the micro environmental changes in the serum albumins. Their antioxidant propensity and antimicrobial study insisted that the compounds displayed good spectrum of activity. Evaluation of their anticancer potential against MCF-7 (human breast cancer) and A549 (human lung carcinoma) cell lines revealed that the complexes exhibited better activity than the ligands and cisplatin. Further, the results of LDH and NO release assays supported the cytotoxic nature of the compounds. The non-toxic nature of the compounds was established by testing against the non-cancerous cell line HaCaT (human normal keratinocyte).
It is inconclusive whether the perioperative administration of systemic lidocaine provides effective postoperative analgesia and enhances recovery in major orthopaedic surgery. We hypothesised that ...in adolescent and adult patients undergoing posterior spinal arthrodesis, a perioperative lidocaine infusion would reduce opioid requirements during the first 24 postoperative h.
70 patients undergoing posterior arthrodesis were enrolled in this prospective, randomised, double-blind, placebo-controlled clinical trial. Patients received total i.v. anaesthesia with propofol and remifentanil and were randomized to an adjuvant therapy with either lidocaine i.v.-bolus injection of 1.5 mg kg−1 at induction of anaesthesia, followed by an infusion of 1.5 mg kg−1 h−1 which was continued until six h after arrival at the post-anaesthesia care unit or placebo (equal volumes of saline). Postoperative pain was treated with patient-controlled i.v. morphine. Primary endpoints of this study were morphine requirements in the first postoperative 24 h.
Systemic lidocaine did not decrease morphine requirements in the first 24 postoperative h lidocaine-group: 48 (23) mg (mean(sd)) vs placebo-group: 51(19) mg, P = 0.22. Likewise, groups were not different with respect to the severity of postoperative pain, morphine consumption after 48 and 72 h, incidence of postoperative nausea and vomiting, perioperative inflammation, time to recovery of intestinal function, hospital length of stay, and quality of life (assessed preoperatively and one month postoperatively using the SF-12 physical and mental composite scores).
In our study, systemic lidocaine had no analgesic benefits in posterior arthrodesis when added to an opioid-based anaesthetic regimen.
Eudra CT 2012-005264-98.
Objectives (1) Evaluate hearing outcomes of patients after planned malleus removal during ossicular chain reconstruction. (2) Analyze hearing results for titanium (Ti) and hydroxyapatite (HA) total ...ossicular prostheses (TOPs) and partial ossicular prostheses (POPs). (3) Compare Ti and HA partial prostheses. Study Design Retrospective case series with chart review. Setting Tertiary health care organization. Subjects and Methods A chart review was conducted of 139 consecutive patients who presented with chronic otitis media with perforation (with or without cholesteatoma) and were treated with initial-stage tympanoplasty (with or without mastoidectomy) and managed with TOP (n = 22) or POP (n = 117) between July 2010 and July 2015. The malleus was completely removed in all cases. Hearing was assessed via bone and air conduction pretone averages (0.5, 1, 2 kHz) pre- and postoperatively. Air-bone gap (ABG) and change in ABG (ΔABG) were analyzed. Pre- and postoperative values were compared. Results The overall mean ABG decreased from 29.4 ± 12.3 dB to 18.2 ± 11.4 dB postoperatively ( P < .001) with a mean ΔABG of 14.5 dB (95% CI, 12.793-16.203). Overall success was achieved by 69.1%. The POP group achieved higher success (70.9%) than the TOP group (59.1%; P = .0001). Mean ABG decreased significantly within surgical groups (TOP and POP) and prosthesis material groups (Ti and HA; all P < .001). Ti had statistically higher success than HA in both techniques: POP ( P = .0478) and TOP ( P = .0251). There was a 98% graft take rate. Conclusion Planned malleus removal during ossicular chain reconstruction, regardless of disease extent, allows for simpler reconstruction and comparable favorable results to preservation of the malleus and should be considered during surgical planning.
Hotels have a variety of internet distribution channels to help them sell rooms, including sites that have come to be called online travel agents (OTAs), or third-party websites, but the cost of ...using these intermediaries is considerable. This article examines how hotels can sell room inventory while maximizing net room revenues—chiefly, by steering customers to their own sites, rather than to the OTAs. Even though hotels want to sell rooms via their own channels, the hotel industry relies heavily on efficient and convenient OTAs to sell rooms. Based on eleven interviews (nine hotels, one third-party website, and one airline), we recommend the following ways to strengthen sales on hotels’ websites: maintain a best-rate guarantee, optimize the website for search engines, mine data from customer profiles to provide custom offers, retain premium rooms for sale on the hotel website, offer discounts or other promotions to customers who book on the hotel website, offer incentives for returning guests who book on the hotel website, avoid giving loyalty points for OTA bookings, and enrich the hotel’s website with information. Because the ability to offer low prices is a chief advantage of OTAs, many hotels have promoted price parity as one strategy for attracting customers. The results of tracking room rates of 13 hotels posted by third-party websites and hotels over a 17-week period demonstrated, however, that room rate parity is rare, even though all selling parties espouse such parity. Parity generally was found only for smaller hotels. The study also found that room rates fall as the date of arrival approaches, and it became clear that individual properties in a hotel chain follow the chain’s overall pricing strategy.
PDF
